Project Grant R44AI191836
Award Date 8/8/25
Completion Date 7/31/26
Dollars Obligated $249K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $1,486,800 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the unexpected role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against Herpes Simplex Virus (HSV). The research involves engineering a novel single-cycle HSV vaccine strain, isolating potent...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on manipulating the DNA damage response and proteome on viral genomes during herpes simplex virus (HSV) infection. The $651,832 award, with a project period from November 2024 to October 2029, will enable researchers at The Children's Hospital of Philadelphia to conduct a multi-modal proteomic...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $236,292 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to conduct research on the herpes simplex virus (HSV) entry glycoprotein complexes. The key objectives are to use new methods to isolate and characterize the structures of HSV glycoprotein complexes, such as GD/GH/GL and GH/GL/GB, which are critical for viral entry into host cells. This...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $658,273 to the University of Massachusetts Medical School to study how Herpes Simplex Virus 1 (HSV-1) interacts with and regulates the NLRP1 inflammasome pathway in human skin cells. The key goals are to identify the mechanisms by which HSV-1 activates and inhibits the NLRP1 inflammasome, and to...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to examine the mechanisms of infection and transduction by a new herpes simplex virus (HSV) gene therapy vector. The key goals are to investigate how the inclusion of internal inverted repeat (IR) sequences in the HSV vector can increase replication and transgene expression, potentially leading...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $999,991 Project Grant to Tendel Therapies Inc. on August 13, 2025. The grant supports the development of an HIV reservoir-depletion agent, BSAB-98, a bispecific antibody that targets CCR5-expressing cells for elimination. Preclinical studies in infant rhesus macaques showed over 50% remission of simian immunodeficiency virus (SIV) after BSAB-98...
- The federal Project Grant award of $7,037,583 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the mechanisms of nuclear egress in herpesviruses. The grant funds a collaborative research project led by Tufts University School of Medicine to expand structural and functional studies of the nuclear egress complex (NEC) across different herpesvirus families, visualize the...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $411,499 to the University of Kansas Center for Research Inc. to study the role of the PARP14 protein in restricting the replication of the Herpes Simplex Virus 1 (HSV-1). The research aims to establish PARP14 as a novel host restriction factor that limits the early stages of HSV-1 replication, which could help...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $258,750 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to HBVTech, LLC, a small disadvantaged business located in Germantown, Maryland. The grant funding supports the development of HBVZ10, a new gene therapy candidate aimed at producing sustained high levels of anti-hepatitis B surface antigen antibodies to block hepatitis B virus (HBV) reinfection and potentially...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of caspase-3 mediated cleavage of VPS4A in restricting herpes simplex virus type 1 (HSV-1) replication. The $109,941 award to the University of Massachusetts Medical School, spanning from May 2025 to June 2029, aims to elucidate the mechanisms by which caspases and programmed cell death...